Abstract
Malignant melanoma represents a serious public health problem and is a deadly disease when it is diagnosed at late stage. Though 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) has been widely used clinically for melanoma imaging, other approaches to specifically identify, characterize, monitor and guide therapeutics for malignant melanoma are still needed. Consequently, many probes targeting general molecular events including metabolism, angiogenesis, hypoxia and apoptosis in melanoma have been successfully developed. Furthermore, probes targeting melanoma associated targets such as melanocortin receptor 1 (MC1R), melanin, etc. have undergone active investigation and have demonstrated high melanoma specificity. In this review, these molecular probes targeting diverse melanoma biomarkers have been summarized. Some of them may eventually contribute to the improvement of personalized management of malignant melanoma.
Keywords: Molecular Imaging, Melanoma, PET, Molecular Probe, MC1R, Melanin
Current Pharmaceutical Biotechnology
Title: Molecular Probes for Malignant Melanoma Imaging
Volume: 11 Issue: 6
Author(s): Gang Ren, Ying Pan and Zhen Cheng
Affiliation:
Keywords: Molecular Imaging, Melanoma, PET, Molecular Probe, MC1R, Melanin
Abstract: Malignant melanoma represents a serious public health problem and is a deadly disease when it is diagnosed at late stage. Though 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) has been widely used clinically for melanoma imaging, other approaches to specifically identify, characterize, monitor and guide therapeutics for malignant melanoma are still needed. Consequently, many probes targeting general molecular events including metabolism, angiogenesis, hypoxia and apoptosis in melanoma have been successfully developed. Furthermore, probes targeting melanoma associated targets such as melanocortin receptor 1 (MC1R), melanin, etc. have undergone active investigation and have demonstrated high melanoma specificity. In this review, these molecular probes targeting diverse melanoma biomarkers have been summarized. Some of them may eventually contribute to the improvement of personalized management of malignant melanoma.
Export Options
About this article
Cite this article as:
Ren Gang, Pan Ying and Cheng Zhen, Molecular Probes for Malignant Melanoma Imaging, Current Pharmaceutical Biotechnology 2010; 11 (6) . https://dx.doi.org/10.2174/138920110792246465
DOI https://dx.doi.org/10.2174/138920110792246465 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Viral Vectors in Cancer Immunotherapy: Which Vector for Which Strategy?
Current Gene Therapy Molecular Phenotyping of Mouse Mutant Resources by RNA Expression Profiling
Current Genomics Plants vs. Cancer: A Review on Natural Phytochemicals in Preventing and Treating Cancers and Their Druggability
Anti-Cancer Agents in Medicinal Chemistry Melanogenesis and Melanosome Transportation Modulators from Medicinal Plants
Letters in Drug Design & Discovery Inflammatory Cytokines, Growth Factors, and Depression
Current Pharmaceutical Design CCL21 and IFNγ Recruit and Activate Tumor Specific T cells in 3D Scaffold Model of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry The PKB/AKT Pathway in Cancer
Current Pharmaceutical Design Systemic Approach to the Study of Complex Bone Disorders at the Whole- Genome Level
Current Genomics Nitric Oxide: Friendly Rivalry in Tuberculosis
Current Signal Transduction Therapy Paraneoplastic Pemphigus: Autoimmune-Cancer Nexus in the Skin
Anti-Cancer Agents in Medicinal Chemistry Role of NF-κB and NF-κB-regulated Gene Products in Chemoresistance and Radioresistance
Current Cancer Therapy Reviews Inhibition of Glycogen Synthase Kinase-3 Reverses Tau Hyperphosphorylation Induced by Pin1 Down-Regulation
CNS & Neurological Disorders - Drug Targets Targeting MAPK Signalling: Prometheus Fire or Pandoras Box?
Current Pharmaceutical Design Mutations in MicroRNA Genes and Their Binding Sites are Infrequently Associated with Human Colorectal Cancer in the Kashmiri Population
MicroRNA Specificity of Binding in Protein Kinases
Current Enzyme Inhibition Gamma-Amino Butyric Acid Inhibits the Nicotine-Imposed Stimulatory Challenge in Xenograft Models of Non-Small Cell Lung Carcinoma
Current Cancer Drug Targets pH-Gradient Incorporation of 9-Nitrocamptothecin in PEGylated Liposomes: Formulation Properties and Efficacy <i>In Vitro</i> and <i>In Vivo</i>
Pharmaceutical Nanotechnology Hematopoietic Stem Cells Therapies
Current Stem Cell Research & Therapy A Nanostructured Silica-Lipid Hybrid to Facilitate Oral SN-38-based Chemotherapy
Drug Delivery Letters Phytotherapeutic Agents for Benign Prostatic Hyperplasia: An Overview
Mini-Reviews in Medicinal Chemistry